-
Patent Agency Ranking
公开(公告)号：US20200172874A1
公开(公告)日：2020-06-04
申请号：US16782579
申请日：2020-02-05
Inventor： Yuki TAKAHASHI , Shiro KITANO , Ryohei KATAYAMA , Satoshi NAGAYAMA
IPC: C12N5/09
Abstract: A primary culture method in which cells contained in a tissue collected from a living body are primary cultured in vitro, in which the cells in the tissue collected from the living body are seeded and cultured on a top surface of a cell structure containing cells constituting a stroma and composed of a single layer or two or more cell layers laminated in the thickness direction.
-
公开(公告)号：US20230407266A1
公开(公告)日：2023-12-21
申请号：US18239938
申请日：2023-08-30
Inventor： Yuki TAKAHASHI , Shiro KITANO , Ryohei KATAYAMA , Satoshi NAGAYAMA
IPC: C12N5/09
CPC classification number: C12N5/0693 , C12N2502/11 , C12N2502/1323 , C12N2502/28 , C12N2509/10 , C12N2513/00 , C12N2533/30 , C12N2533/90
Abstract: A primary culture method in which cells contained in a tissue collected from a living body are primary cultured in vitro, in which the cells in the tissue collected from the living body are seeded and cultured on a top surface of a cell structure containing cells constituting a stroma and composed of a single layer or two or more cell layers laminated in the thickness direction.
-
公开(公告)号：US20240426809A1
公开(公告)日：2024-12-26
申请号：US18750552
申请日：2024-06-21
Inventor： Yuki TAKAHASHI , Yuma YOKOKAWA , Ryohei KATAYAMA
Abstract: A evaluation method of an anticancer drug includes culturing a cell structure containing a cancer cell and a stromal cell in a presence of one or two or more of anticancer drugs and evaluating an anticancer effect of the anticancer drug using, as an index, the number of cells having a proliferation ability of the cancer cell in the cell structure after the culturing, in which a signal transduction pathway in the cancer cell stimulated by a hepatocyte growth factor, a placental growth factor, or a vascular endothelial growth factor is more activated than a signal transduction pathway in a normal cell.
-
公开(公告)号：US20190160066A1
公开(公告)日：2019-05-30
申请号：US16302207
申请日：2017-05-17
Applicant: JAPANESE FOUNDATION FOR CANCER RESEARCH
Inventor： Ryohei KATAYAMA , Ken UCHIBORI , Naoya FUJITA
IPC: A61K31/506 , A61K31/662 , G01N33/574 , A61P35/00
Abstract: A drug containing, as an active ingredient, a compound represented by ALK inhibitors such as brigatinib, AP26113-analog, and AZD3463 has been found to be effective against a non-small cell lung cancer having a point mutation at C797S in EGFR which has acquired a resistance to chemotherapy agents. Further, the drug used in combination with an anti-EGFR antibody demonstrates a notable suppression effect on the tumor growth. The drug has a potential to be a therapeutic agent effective against a non-small cell lung cancer which is resistant to gefitinib, a first generation therapeutic agent and osimertinib, a third generation therapeutic agent.
-
5.发明申请公开(公告)号：US20190017125A1
公开(公告)日：2019-01-17
申请号：US16076886
申请日：2017-02-07
Applicant: JAPANESE FOUNDATION FOR CANCER RESEARCH
Inventor： Kengo TAKEUCHI , Kana SAKAMOTO , Ryohei KATAYAMA , Seiji SAKATA
IPC: C12Q1/6886 , A61K31/167 , A61K31/4045 , A61K31/635 , G01N33/50 , A61K31/55 , A61K31/675
Abstract: The diagnostic markers that provide novel diagnostic criteria to blastic plasmacytoid dendritic cell neoplasm (BPDCN) has been searched, and the presence of immunoblastoid cytomorphology, 8q24 rearrangement, and MYC expression were established as novel markers for subtyping BPDCN. It has been further found that the inhibitors which directly or indirectly inhibit the expression, functions, or signaling pathways of MYC, such as BET bromodomain-selective inhibitors or aurora kinase inhibitors, are effective in MYC-positive BPDCN, and HDAC inhibitors or BCL2 family protein inhibitors are effective as therapeutic drugs for BPDCN.
-
-
-
-
Search Results
5
records
(took 0.012 seconds)
